1,6-dichloro-3-(4-fluorophenyl)-2,3-dihydro-1H-indene | 153627-82-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 1,6-dichloro-3-(4-fluorophenyl)-2,3-dihydro-1H-indene
• 英文别名: 3,5-dichloro-1-(4-fluorophenyl)-2,3-dihydro-1H-indene
• CAS: 153627-82-8
• 化学式: C₁₅H₁₁Cl₂F
• 分子量: 281.157
• InChiKey: AQBZXUVIFCIHMH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1,6-dichloro-3-(4-fluorophenyl)-2,3-dihydro-1H-indene 在 甲酸 、 potassium carbonate 作用下， 以 丙酮 为溶剂， 反应 20.0h， 生成 4-[(1S,3R)-6-chloro-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-1-methyl-1,4-diazaspiro[5.5]undecane
  参考文献：
  名称：

  Enhanced D1 Affinity in a Series of Piperazine Ring Substituted 1-Piperazino-3-Arylindans with Potential Atypical Antipsychotic Activity

  摘要：

  A study of the effect of aromatic substitution on D-1 and D-2 affinity in a series of previously reported trans-1-piperazino-3-phenylindans shows similar structure-activity relationships for the two receptor sites. 6-Substituted derivatives have affinity for both receptors, and 6-chloro- or B-fluoro-substituted derivatives show preference for D-1 receptors. D-1 affinity and selectivity are significantly increased in a series of new piperazine ring substituted derivatives. Potent D-1 and D-2 antagonism in vivo are confined to derivatives with relatively small substituents in the 2-position of the piperazine ring (e.g. 2-methyl, 2,2-dimethyl, 2-spirocyclobutyl or 2-spirocyclopentyl). Consequently, the effect of aromatic substitution is examined in a series of 1-(2,2-dimethylpiperazino)-3-arylindans. All these compounds except the 4-, 5-, 7- and 4'-chlorosubstituted derivatives have potent D-1 affinity (IC50's below 10 nM) and the majority of the compounds antagonize SK&F 38393-induced circling in 6-OHDA-lesioned rats with ED(50) values about 1 mu mol/kg. In vitro all compounds show preference for D-1 receptors, but in vivo they are equally effective as D-1 and D-2 antagonists. The compounds have high affinity for 5-HT2 receptors and selected compounds show high affinity for alpha(1) adrenoceptors. Furthermore, a subgroup consisting of (-)-38, (-)-39, (-)-41, and (-)-54 does not induce catalepsy in rats. These compounds have the potential of being ''atypical'' antipsychotics and have consequently been selected for further studies. The non-receptor-blocking enantiomers are shown to be inhibitors of DA and NE uptake in accordance with previous observations in compounds unsubstituted in the piperazine ring. Two compounds, (+)-38 and (+)-40, block DA uptake with IC50 values below 10 nM. Finally, the observed structure-activity relationships are discussed in relation to previously published pharmacophore models for D-2 and 5-HT2 receptors. It is concluded that the piperazine substituents might induce a different binding mode at the dopamine receptor sites, perhaps only at the D-1 receptor site.

  DOI：

  10.1021/jm00022a004
• 作为产物：
  描述：

  2-溴-4-氯苯甲醛 在 哌啶 、 sodium tetrahydroborate 、 正丁基锂 、 氯化亚砜 、 硫酸 、 magnesium 、 溶剂黄146 作用下， 以 甲醇 、 乙醚 、 正己烷 、 甲苯 为溶剂， 反应 28.0h， 生成 1,6-dichloro-3-(4-fluorophenyl)-2,3-dihydro-1H-indene
  参考文献：
  名称：

  Neuroleptic activity and dopamine-uptake inhibition in 1-piperazino-3-phenylindans

  摘要：

  A series of 1-piperazino-3-phenylindans was synthesized and tested for neuroleptic and thymoleptic activity. Neuroleptic activity was found only in trans racemates and was associated with one of the enantiomers only. The potent and long-acting neuroleptic compound trans-4-[3-(4-fluorophenyl)-6-(trifluoromethyl)indan-1-yl]-1-piperazineethanol (Lu 18-012, tefludazine) was developed by systematic variation of structural components. Thymoleptic activity was optimized, especially with respect to dopamine-uptake inhibition. No geometrical stereoselectivity was found with regard to dopamine-uptake inhibition, but a high enantioselectivity could be demonstrated for both cis and trans racemates. The most potent compounds were 1-piperazino-3-(3,4-dichlorophenyl)indans with IC50 values of about 2nM for inhibition of dopamine uptake.

  DOI：

  10.1021/jm00361a002

文献信息

• 1-piperazino-1,2-dihydroindene derivatives
  申请人：H. Lundbeck A/S

  公开号：US05807855A1

  公开（公告）日：1998-09-15

  Trans isomers of 1-piperazino-1,2-dihydroindene compounds having formula (I), ##STR1## wherein X and Y are hydrogen, halogen, trifluoromethyl, alkyl, alkylthio, trifluoromethylthio, alkoxy, hydroxy, alkylsulfonyl, amino, alkylamino, nitro or cyano; Ar is a phenyl, thienyl or furyl group, each optionally substituted; R.sub.1 is hydrogen, or optionally hydroxy substituted alkyl, alkenyl, cycloalkyl or cycloalkylalkyl; R.sub.2 is alkyl, alkenyl, cycloalkyl, or cycloalkylalkyl; or R.sub.1 and R.sub.2 together form a 5 to 7-membered heterocyclic ring fused with the piperazine ring, which ring may be substituted with hydroxy; R.sub.3 is hydrogen, alkyl, alkenyl, cycloalkyl or cycloalkylalkyl; or R.sub.2 and R.sub.3 together form a 3 to 7-membered carbocyclic ring which is spiro-fused to the piperazine ring; and R.sub.4 is hydrogen or alkyl. The compounds of the invention have potent antagonist action on dopamine D.sub.1 receptors and are useful in the treatment of diseases of the central nervous system, such as psychoses, schizophrenia (positive as well as negative symptoms), anxiety, depression, sleep disturbances, migraine, Parkinson's disease or cocaine abuse.

  公式（I）的1-哌嗪基-1,2-二氢吲哚化合物的反式异构体，其化学式为：##STR1## 其中X和Y为氢、卤素、三氟甲基、烷基、烷基硫、三氟甲基硫、烷氧基、羟基、烷基磺酰基、氨基、烷基氨基、硝基或氰基；Ar为苯基、噻吩基或呋喃基，每个基团均可选择地被取代；R.sub.1为氢，或者是可选择地被羟基取代的烷基、烯基、环烷基或环烷基烷基；R.sub.2为烷基、烯基、环烷基或环烷基烷基；或者R.sub.1和R.sub.2共同形成一个与哌嗪环融合的5至7成员杂环，该环可能被羟基取代；R.sub.3为氢、烷基、烯基、环烷基或环烷基烷基；或者R.sub.2和R.sub.3共同形成一个与哌嗪环螺合的3至7成员碳环；R.sub.4为氢或烷基。本发明的化合物在多巴胺D.sub.1受体上具有强效的拮抗作用，并可用于治疗中枢神经系统疾病，如精神病、精神分裂症（正性和负性症状）、焦虑、抑郁、睡眠障碍、偏头痛、帕金森病或可卡因滥用。
• 1-PIPERAZINO-1,2-DIHYDROINDENE DERIVATIVES
  申请人：H. LUNDBECK A/S

  公开号：EP0638073B1

  公开（公告）日：2000-06-21
• BOGESO, K. P., J. MED. CHEM., 1983, 26, N 7, 935-947
  作者：BOGESO, K. P.

  DOI：——

  日期：——
• US5807855A
  申请人：——

  公开号：US5807855A

  公开（公告）日：1998-09-15
• Enhanced D1 Affinity in a Series of Piperazine Ring Substituted 1-Piperazino-3-Arylindans with Potential Atypical Antipsychotic Activity
  作者：Klaus P. Bogeso、Jorn Arnt、Kristen Frederiksen、Hans Otto Hansen、John Hyttel、Henrik Pedersen

  DOI：10.1021/jm00022a004

  日期：1995.10

  A study of the effect of aromatic substitution on D-1 and D-2 affinity in a series of previously reported trans-1-piperazino-3-phenylindans shows similar structure-activity relationships for the two receptor sites. 6-Substituted derivatives have affinity for both receptors, and 6-chloro- or B-fluoro-substituted derivatives show preference for D-1 receptors. D-1 affinity and selectivity are significantly increased in a series of new piperazine ring substituted derivatives. Potent D-1 and D-2 antagonism in vivo are confined to derivatives with relatively small substituents in the 2-position of the piperazine ring (e.g. 2-methyl, 2,2-dimethyl, 2-spirocyclobutyl or 2-spirocyclopentyl). Consequently, the effect of aromatic substitution is examined in a series of 1-(2,2-dimethylpiperazino)-3-arylindans. All these compounds except the 4-, 5-, 7- and 4'-chlorosubstituted derivatives have potent D-1 affinity (IC50's below 10 nM) and the majority of the compounds antagonize SK&F 38393-induced circling in 6-OHDA-lesioned rats with ED(50) values about 1 mu mol/kg. In vitro all compounds show preference for D-1 receptors, but in vivo they are equally effective as D-1 and D-2 antagonists. The compounds have high affinity for 5-HT2 receptors and selected compounds show high affinity for alpha(1) adrenoceptors. Furthermore, a subgroup consisting of (-)-38, (-)-39, (-)-41, and (-)-54 does not induce catalepsy in rats. These compounds have the potential of being ''atypical'' antipsychotics and have consequently been selected for further studies. The non-receptor-blocking enantiomers are shown to be inhibitors of DA and NE uptake in accordance with previous observations in compounds unsubstituted in the piperazine ring. Two compounds, (+)-38 and (+)-40, block DA uptake with IC50 values below 10 nM. Finally, the observed structure-activity relationships are discussed in relation to previously published pharmacophore models for D-2 and 5-HT2 receptors. It is concluded that the piperazine substituents might induce a different binding mode at the dopamine receptor sites, perhaps only at the D-1 receptor site.